2025.11.20
Precisely targeting tumor cells while sparing healthy tissues has long been a central goal for researchers. A recent study published in Antibodies ingeniously leverages the acidic microenvironment of tumors to develop a pH‑dependent anti‑AXL antibody, offering a novel approach to addressing the challenge of off‑target toxicity in targeted therapies.
2025.08.29
“Targeting” the Lead: The Next-Generation Star of Immunotherapy—AOAH!
Recently, Cell published a research paper titled “Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy.” Using the innovative Cancer Immunology Data Engine (CIDE) system, the study analyzed 8,575 tumor‑omics datasets from 5,957 patients and identified AOAH—among 1,903 human secreted proteins—as the most prominent candidate for enhancing immunotherapy.
2025.06.10
Monoclonal antibodies, owing to their high specificity and strong affinity for antigens, have become the predominant class in antibody‑drug development. However, as research has advanced, their limitations have become increasingly apparent, including a finite number of antigen‑binding events and the potential to trigger unintended antibody clearance and antigen accumulation effects.
2025.06.06
Through analysis of human kidney gene expression and methylation patterns, the authors found that the CHAC1 gene, located on chromosome 15 and encoding glutathione-specific γ-glutamyltransferase 1, is influenced by genetic variants associated with kidney disease in genome-wide association studies (GWAS).
2025.05.23
“Target” Seizes the Initiative | A New Antiviral Target, SAMD9, Has Been Discovered!
Double-stranded DNA (dsDNA) or double-stranded RNA (dsRNA) originating from microorganisms or endogenous sources can be recognized by the cell’s innate immune system, triggering an immune response.
2025.05.16
“Targeting” the Lead: The Key Target GHS‑R1a Marks a New Breakthrough in Anxiety Disorder Treatment!
Anxiety disorders are a mental illness that affects hundreds of millions of people worldwide, yet existing treatments have limited efficacy and significant side effects.
2025.05.09
“Targeting” the Advantage: A Novel Immune Checkpoint, ITPRIPL1 (CD3L1), Independent of PD-1
In the T cell–mediated antitumor immune response, the T cell receptor (TCR)–CD3 complex occupies a pivotal position; however, research on its endogenous inhibitory ligands has long remained virtually unexplored.
2025.03.27
“Targeting” the Lead: The Next PD‑1? Exploring the SOX17 Target
The immune system serves as the body’s primary defense against tumors; however, cancer cells often employ “immune evasion” mechanisms to disguise themselves and evade recognition and attack by immune cells. Although immune checkpoint therapies, exemplified by PD‑1/PD‑L1 inhibitors, have achieved remarkable progress in advanced cancers, their efficacy remains limited for early-stage tumors, such as colorectal cancer.
2025.01.09
Xi News | Synthetic Fab HuCAL GOLD Library Screening Helps Fizezumab Advance Toward Market Launch
On January 8, 2025, the marketing application for Fasenra, a CD38‑targeting antibody injection developed by Tianjing Biologics, was accepted by the NMPA. This landmark advancement undoubtedly heralds new hope for second‑line treatment of patients with multiple myeloma.
2025.01.05
The commercial development of antibody therapies is a global endeavor, involving tens of thousands of biopharmaceutical companies and supporting service providers. To date, their collective efforts have brought more than 200 antibody therapies to market, with nearly 1,400 additional product candidates in the pipeline currently undergoing clinical evaluation for the treatment of a wide range of diseases.
20
2025
/
11
10
2025
/
06
06
2025
/
06
Subscription Information
Subscribe to receive updates from Xichang News.
Shanghai Constream biotechnology Co., Ltd
Phone:021-59255902
Address: Building 2, Floors 2–3, Lane 10688, Beiqing Road, Qingpu District, Shanghai
WeChat Official Account
Copyright © 2026 Shanghai Constream biotechnology Co., Ltd.